Daniel Ledbetter
University of Texas MD Anderson Cancer Center
Induced pluripotent stem cellFusion geneCancerPhenocopyTelomerase reverse transcriptaseIDH1Gene deliveryViral replicationPermissiveRNA interferenceChemistrySmall hairpin RNAIn vitroMicrovesiclesBreakpointSmall interfering RNAVirusProliferative indexGlioblastomaOncolytic adenovirusHuman brainGliomaHamsterStem cellMurine modelSurgical resectionTumor cellsOrganoidCancer researchViability assayMedicineIntracellularCell cultureOncolytic virusBiologyImmune system
11Publications
1H-index
1Citations
Publications 13
Newest
#1Yuzaburo ShimizuH-Index: 3
#2Joy GuminH-Index: 28
Last. Juan FueyoH-Index: 58
view all 0 authors...
OBJECTIVE Delta-24-RGD is an oncolytic adenovirus that is capable of replicating in and killing human glioma cells. Although intratumoral delivery of Delta-24-RGD can be effective, systemic delivery would improve its clinical application. Bone marrow-derived human mesenchymal stem cells (BM-hMSCs) obtained from healthy donors have been investigated as virus carriers. However, it is unclear whether BM-hMSCs can be derived from glioma patients previously treated with marrow-toxic chemotherapy or w...
Source
#1Lynette Phillips (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Shoudong Li (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. Frederick F. Lang (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 13 authors...
BACKGROUND Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is b...
Source
#2Anwar HossainH-Index: 20
Last. Sricharan GopakumarH-Index: 2
view all 0 authors...
Source
#1Malcolm F. McDonald (BCM: Baylor College of Medicine)
#2Anwar Hossain (University of Texas MD Anderson Cancer Center)H-Index: 20
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 13 authors...
Source
#1Lynette Phillips (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Joy Gumin (University of Texas MD Anderson Cancer Center)H-Index: 28
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 10 authors...
Source
#1Sanjay K. Singh (University of Texas MD Anderson Cancer Center)H-Index: 21
#2Maxime Munyeshyaka (University of Texas MD Anderson Cancer Center)
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 8 authors...
Source
#1Maxime Munyeshyaka (Carleton College)
#2Sanjay K. Singh (University of Texas MD Anderson Cancer Center)H-Index: 21
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 6 authors...
Glioblastomas (GBM) are malignant Grade IV tumors whose prognosis for patients remains dismal, with median survival of 14.6 months after the standard therapy. GBMs have a high proliferative index and are highly invasive to normal brain tissue. GBMs characteristically exhibit areas of necrosis and recruitment of abnormal blood vessels. The most common form of GBMs are primary GBMs (~95%), with no prior clinical history and have poor clinical outcome. Secondary GBMs arise from lower-grade gliomas ...
Source
#1Brittany C. Parker Kerrigan (University of Texas MD Anderson Cancer Center)H-Index: 9
#2Daniel Ledbetter (University of Texas MD Anderson Cancer Center)H-Index: 1
Last. David Cogdell (University of Texas MD Anderson Cancer Center)H-Index: 28
view all 13 authors...
Background Fusion genes form as a result of abnormal chromosomal rearrangements linking previously separate genes into one transcript. The FGFR3-TACC3 fusion gene (F3-T3) has been shown to drive gliomagenesis in glioblastoma (GBM), a cancer that is notoriously resistant to therapy. However, successful targeting of F3-T3 via small molecular inhibitors has not revealed robust therapeutic responses, and specific targeting of F3-T3 has not been achieved heretofore. Here, we demonstrate that depletin...
Source
#1Sricharan Gopakumar (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Joy Gumin (University of Texas MD Anderson Cancer Center)H-Index: 28
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 9 authors...
Source
#1Malcolm McDonald (University of Texas MD Anderson Cancer Center)
#2Irtiza Hasan (University of Texas MD Anderson Cancer Center)H-Index: 4
Last. Frederick Lang (University of Texas MD Anderson Cancer Center)H-Index: 10
view all 13 authors...
Source